Vanda, Probiomed in deal for schizophrenia drug Fanapt for Mexico
This article was originally published in Scrip
Executive Summary
Vanda Pharmaceuticals, the Rockville, Maryland-based developer of products for CNS disorders, has entered into an exclusive licence agreement with Probiomed SA, the pharmaceutical operating unit of Proquifin SA, for the commercialisation of the twice-daily, oral atypical antipsychotic Fanapt (iloperidone) in Mexico. Fanapt is Vanda's first commercial product.